140 related articles for article (PubMed ID: 27721355)
1. Induction of Drug Transporters Alters Disposition of Risperidone - A Study in Mice.
Holthoewer D; Hiemke C; Schmitt U
Pharmaceutics; 2010 Jun; 2(2):258-274. PubMed ID: 27721355
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice.
Kirschbaum KM; Henken S; Hiemke C; Schmitt U
Behav Brain Res; 2008 Apr; 188(2):298-303. PubMed ID: 18164477
[TBL] [Abstract][Full Text] [Related]
3. ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety.
Gunes A; Spina E; Dahl ML; Scordo MG
Ther Drug Monit; 2008 Oct; 30(5):628-33. PubMed ID: 18708991
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome P450 3A inhibitor itraconazole affects plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients.
Jung SM; Kim KA; Cho HK; Jung IG; Park PW; Byun WT; Park JY
Clin Pharmacol Ther; 2005 Nov; 78(5):520-8. PubMed ID: 16321618
[TBL] [Abstract][Full Text] [Related]
5. [Therapeutic drug monitoring of risperidone and its active metabolite 9-hydroxyrisperidone in the treatment of schizophrenia].
Baymeeva NV; Platova AI; Kaleda VG; Miroshnichenko II
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(3):24-28. PubMed ID: 31089091
[TBL] [Abstract][Full Text] [Related]
6. The Differential Binding of Antipsychotic Drugs to the ABC Transporter P-Glycoprotein Predicts Cannabinoid-Antipsychotic Drug Interactions.
Brzozowska NI; de Tonnerre EJ; Li KM; Wang XS; Boucher AA; Callaghan PD; Kuligowski M; Wong A; Arnold JC
Neuropsychopharmacology; 2017 Oct; 42(11):2222-2231. PubMed ID: 28272498
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of risperidone and 9-hydroxyrisperidone in patients with acute episodes associated with bipolar I disorder.
Vermeulen A; Piotrovsky V; Ludwig EA
J Pharmacokinet Pharmacodyn; 2007 Apr; 34(2):183-206. PubMed ID: 17136449
[TBL] [Abstract][Full Text] [Related]
8. Blonanserin, a novel atypical antipsychotic agent not actively transported as substrate by P-glycoprotein.
Inoue T; Osada K; Tagawa M; Ogawa Y; Haga T; Sogame Y; Hashizume T; Watanabe T; Taguchi A; Katsumata T; Yabuki M; Yamaguchi N
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct; 39(1):156-62. PubMed ID: 22691713
[TBL] [Abstract][Full Text] [Related]
9. P-glycoprotein inhibition potentiates the behavioural and neurochemical actions of risperidone in rats.
Pacchioni AM; Gabriele A; Donovan JL; DeVane CL; See RE
Int J Neuropsychopharmacol; 2010 Sep; 13(8):1067-77. PubMed ID: 19835667
[TBL] [Abstract][Full Text] [Related]
10. Effects of single or repeated silymarin administration on pharmacokinetics of risperidone and its major metabolite, 9-hydroxyrisperidone in rats.
Lee KS; Chae SW; Park JH; Park JH; Choi JM; Rhie SJ; Lee HJ
Xenobiotica; 2013 Mar; 43(3):303-10. PubMed ID: 23205514
[TBL] [Abstract][Full Text] [Related]
11. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein.
Wang JS; Ruan Y; Taylor RM; Donovan JL; Markowitz JS; DeVane CL
Int J Neuropsychopharmacol; 2004 Dec; 7(4):415-9. PubMed ID: 15683552
[TBL] [Abstract][Full Text] [Related]
12. Determination of risperidone and 9-hydroxyrisperidone in human plasma by high-performance liquid chromatography: application to therapeutic drug monitoring in Japanese patients with schizophrenia.
Nagasaki T; Ohkubo T; Sugawara K; Yasui N; Furukori H; Kaneko S
J Pharm Biomed Anal; 1999 Mar; 19(3-4):595-601. PubMed ID: 10704125
[TBL] [Abstract][Full Text] [Related]
13. ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice.
Brzozowska N; Li KM; Wang XS; Booth J; Stuart J; McGregor IS; Arnold JC
PeerJ; 2016; 4():e2081. PubMed ID: 27257556
[TBL] [Abstract][Full Text] [Related]
14. [Development and identifiability analysis of parent-metabolite pharmacokinetic model for risperidone and its main active metabolite 9-hydroxyrisperidone].
Ding JJ; Jiao Z; Yu YQ; Shi XJ
Yao Xue Xue Bao; 2007 Jun; 42(6):631-8. PubMed ID: 17702401
[TBL] [Abstract][Full Text] [Related]
15. An evaluation of using rat-derived single-dose neuropharmacokinetic parameters to project accurately large animal unbound brain drug concentrations.
Doran AC; Osgood SM; Mancuso JY; Shaffer CL
Drug Metab Dispos; 2012 Nov; 40(11):2162-73. PubMed ID: 22899853
[TBL] [Abstract][Full Text] [Related]
16. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes.
Ono S; Mihara K; Suzuki A; Kondo T; Yasui-Furukori N; Furukori H; de Vries R; Kaneko S
Psychopharmacology (Berl); 2002 Jun; 162(1):50-4. PubMed ID: 12107617
[TBL] [Abstract][Full Text] [Related]
17. Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients.
Roh HK; Kim CE; Chung WG; Park CS; Svensson JO; Bertilsson L
Eur J Clin Pharmacol; 2001 Nov; 57(9):671-5. PubMed ID: 11791898
[TBL] [Abstract][Full Text] [Related]
18. Effect of cyamemazine on the steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: a preliminary retrospective study.
Lancelin F; Bourcier E; Le Masson V; Lemeille Y; Brovedani S; Paubel P; Piketty ML
Ther Drug Monit; 2010 Dec; 32(6):757-61. PubMed ID: 21068648
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein.
Wang JS; Zhu HJ; Markowitz JS; Donovan JL; DeVane CL
Psychopharmacology (Berl); 2006 Sep; 187(4):415-23. PubMed ID: 16810505
[TBL] [Abstract][Full Text] [Related]
20. Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia.
Mihara K; Kondo T; Yasui-Furukori N; Suzuki A; Ishida M; Ono S; Kubota T; Iga T; Takarada Y; de Vries R; Kaneko S
Ther Drug Monit; 2003 Jun; 25(3):287-93. PubMed ID: 12766554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
